Lv32
248 积分 2025-01-07 加入
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050
9天前
已完结
Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis: A systematic review and network meta-analysis
1个月前
已完结
Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis: A systematic review and network meta-analysis
1个月前
已关闭
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已完结
Vitiligo-like leucoderma following cyclin-dependent kinase 4 and 6 inhibitor treatment: systematic review of the literature
2个月前
已关闭
Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib
2个月前
已关闭
Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib
2个月前
已关闭
Significant Influence of Abemaciclib on Rivaroxaban
2个月前
已完结
皖公网安备34019202002308
